Bafilomycin
 | |
| Names | |
|---|---|
| IUPAC name
(3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16- [(1S,2R,3S)-3-[(2R,4R,5S,6R)-2,4-dihydroxy-6- isopropyl-5-methyl-2-tetrahydropyranyl]-2- hydroxy-1-methylbutyl]-8-hydroxy-3,15- dimethoxy-5,7,9,11-tetramethyl-1- oxacyclohexadeca-3,5,11,13-tetraen-2-one | |
| Identifiers | |
88899-55-2  | |
| ChEMBL | ChEMBL290814 |
| ChemSpider | 10251049  |
| DrugBank | DB06733 |
| PubChem | 6436223 |
| Properties | |
| C35H58O9 | |
| Molar mass | 622.83 g/mol |
| Appearance | Yellow powder |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| verify (what is ?) | |
| Infobox references | |
The bafilomycins are a family of toxic macrolide antibiotic derived from Streptomyces griseus. These compounds all appear in the same fermentation and have quite similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase.
The most used bafilomycin is bafilomycin A1. This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.
Bafilomycin has antibacterial, antifungal, antineoplastic, immunosuppressive activities. In addition, bafilomycin A1 has antimalarial activity [2] It has been shown to decrease multi-drug resistance.
Bafilomycin B1 has been mentioned as a potential antiosteoporotic agent in treating bone lytic diseases.
References
- ↑ Bafilomycin A1 product page from Fermentek
- ↑ van Schalkwyk DA, Chan XW, Misiano P, Gagliardi S, Farina C, Saliba KJ. "Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives results in rapid parasite death" Biochem Pharmacol. 2010 May 1;79(9):1291-9. PMID 20067768
This article is issued from Wikipedia - version of the Monday, November 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.